Understanding Schizophrenia: A Comprehensive Guide to Symptoms, Causes, and Treatment Options

Schizophrenia is a complex mental health condition that affects approximately 1% of the global population, causing significant changes in thinking, perception, emotions, and behavior. This brain disorder typically emerges in late adolescence or early adulthood, with symptoms usually appearing between ages 16 and 30. While schizophrenia presents unique challenges for those affected and their families, advances in treatment have made recovery and meaningful life participation increasingly possible with proper support and intervention.

Recent research has transformed our understanding of schizophrenia from a single disease to a heterogeneous syndrome with multiple contributing factors and varied presentations. The condition affects multiple brain systems and involves complex interactions between genetic vulnerabilities, environmental factors, and neurodevelopmental processes. Despite these complexities, early intervention and comprehensive treatment approaches have shown remarkable success in improving outcomes and quality of life for people living with schizophrenia.

What Is Schizophrenia?
Signs and Symptoms
Types and Diagnosis
Causes and Risk Factors
Brain Changes in Schizophrenia
Treatment Options
Early Intervention Programs
Living with Schizophrenia
Frequently Asked Questions
How Therapy Can Help

What Is Schizophrenia?

Schizophrenia is a serious brain disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. People with schizophrenia may experience difficulty distinguishing between what is real and what is not, leading to significant challenges in daily functioning. The term schizophrenia comes from Greek roots meaning "split mind," though this refers to a fragmentation of mental functions rather than multiple personalities.

According to recent data from the National Institute of Mental Health, schizophrenia affects how a person thinks, feels, and behaves. The condition involves abnormal interpretation of reality, where individuals don't know what sights, sounds, and experiences are real or what they are imagining. This can result in profound difficulties with work, relationships, self-care, and community participation.

The impact of schizophrenia extends beyond the individual to families and communities. Nearly one in five privately insured patients who received medical services were diagnosed with mental health conditions in 2023, with regional variations showing the Midwest having the highest percentage at 21.3%. Understanding schizophrenia as a treatable condition rather than an insurmountable challenge is crucial for reducing stigma and promoting recovery.

Signs and Symptoms

The symptoms of schizophrenia are diverse and can vary significantly between individuals. Mental health professionals typically categorize these symptoms into three main groups: positive symptoms, negative symptoms, and cognitive symptoms.

Positive Symptoms

Positive symptoms represent experiences added to normal functioning and include:

Hallucinations: Seeing, hearing, feeling, or smelling things that aren't actually present. Auditory hallucinations (hearing voices) are the most common
Delusions: Fixed false beliefs that persist despite contrary evidence, such as:
Persecutory delusions (believing others are plotting harm)
Referential delusions (thinking everyday events have special personal meaning)
Grandiose delusions (believing one has exceptional abilities or importance)
Control delusions (feeling that external forces control one's thoughts or actions)
Disorganized thinking and speech: Difficulty organizing thoughts, jumping between unrelated topics, or speaking incoherently
Abnormal motor behavior: Unusual movements, agitation, or catatonia (lack of movement or response)

Negative Symptoms

Negative symptoms involve the absence or reduction of normal functions:

Diminished emotional expression: Reduced facial expressions, monotone voice, limited eye contact
Avolition: Decreased motivation to initiate or sustain activities
Anhedonia: Reduced ability to experience pleasure
Asociality: Social withdrawal and decreased interest in relationships
Alogia: Poverty of speech or reduced verbal communication

Recent research on negative symptoms shows they significantly impact functional outcomes and require specialized therapeutic approaches.

Cognitive Symptoms

Cognitive symptoms affect thinking processes and include:

Impaired attention and concentration
Working memory deficits
Difficulty with executive functioning (planning, organizing, decision-making)
Problems with processing speed
Challenges in social cognition (understanding social cues and others' mental states)

Early Warning Signs

Recognizing early warning signs is crucial for timely intervention. These may include:

Social isolation and withdrawal
Declining academic or work performance
Unusual suspiciousness or paranoid thoughts
Difficulty concentrating or confused thinking
Changes in sleep patterns
Increased sensitivity to sensory stimuli
Depressed mood or anxiety
Substance use as a coping mechanism

People are usually first diagnosed with schizophrenia between the ages of 16 and 30, after the first episode of psychosis, though subtle changes often precede the first psychotic episode by months or years.

Types and Diagnosis

Current Diagnostic Approach

The diagnostic approach to schizophrenia has evolved significantly. Schizophrenia is increasingly considered to be a heterogeneous syndrome and not a singular disease entity. There is no necessary or sufficient etiology, pathology, set of clinical features, or treatment that fully circumscribes this syndrome.

According to the DSM-5-TR (2022), a diagnosis of schizophrenia requires:

1. Two or more of the following symptoms present for at least one month:

Delusions
Hallucinations
Disorganized speech
Grossly disorganized or catatonic behavior
Negative symptoms

1. At least one symptom must be delusions, hallucinations, or disorganized speech

2. Significant functional impairment in work, relationships, or self-care

3. Continuous signs of disturbance for at least six months

Historical Subtypes (No Longer Used)

The DSM-5 eliminated the previous subtypes of schizophrenia (paranoid, disorganized, catatonic, residual, and undifferentiated) because research showed they didn't help with diagnosis or treatment planning. Instead, clinicians now use a dimensional approach that considers the severity and predominance of different symptom domains.

Spectrum Approach

Modern understanding places schizophrenia within a broader spectrum of psychotic disorders, including:

Schizophreniform disorder: Similar symptoms lasting 1-6 months
Brief psychotic disorder: Symptoms lasting less than one month
Schizoaffective disorder: Combined features of schizophrenia and mood disorders
Delusional disorder: Primarily involves delusions without other psychotic symptoms
Schizotypal personality disorder: Milder, persistent odd behaviors and thoughts

Differential Diagnosis

Accurate diagnosis requires ruling out other conditions that can mimic schizophrenia:

Substance-induced psychotic disorders
Medical conditions affecting the brain
Mood disorders with psychotic features
Autism spectrum disorders with psychotic symptoms
Severe PTSD with dissociative features

Causes and Risk Factors

Schizophrenia results from complex interactions between multiple risk factors rather than a single cause. Genetic risk factors likely include thousands of common genetic variants that each have a small impact on an individual's risk and a plethora of rare gene variants that have a larger individual impact on risk. Their biological effects are concentrated in the brain and many of the same variants also increase the risk of other psychiatric disorders.

Genetic Factors

Family history: Having a first-degree relative with schizophrenia increases risk by approximately 10%
Twin studies: If one identical twin has schizophrenia, the other has about a 50% chance of developing it
Polygenic risk: Researchers analyzing genomic data from over 24,000 people with schizophrenia and 97,000 people without schizophrenia identified 10 genes with ultra-rare coding variants significantly associated with schizophrenia
Shared genetic risk: Many genetic variants associated with schizophrenia also increase risk for bipolar disorder, autism, and other neurodevelopmental conditions

Environmental Risk Factors

Environmental risk factors include but are not limited to urban residence in childhood, migration, older paternal age at birth, cannabis use, childhood trauma, antenatal maternal infection, and perinatal hypoxia. Additional factors include:

Prenatal exposures: Maternal infections, malnutrition, or stress during pregnancy
Birth complications: Oxygen deprivation, premature birth, low birth weight
Childhood adversity: Trauma, abuse, neglect, or bullying
Social factors: Social isolation, discrimination, or minority stress
Substance use: Particularly cannabis use during adolescence

Neurodevelopmental Factors

Current evidence suggests schizophrenia involves altered brain development beginning before birth and continuing through early adulthood:

Disrupted neuronal migration during fetal development
Abnormal synaptic pruning during adolescence
Altered myelination affecting brain connectivity
Disrupted maturation of inhibitory neural circuits

Stress-Vulnerability Model

The stress-vulnerability model proposes that individuals inherit or acquire a vulnerability to schizophrenia, and environmental stressors can trigger symptom onset in vulnerable individuals. This model emphasizes:

Individual differences in stress sensitivity
The protective role of coping skills and social support
The importance of stress management in treatment
Opportunities for prevention through risk reduction

Brain Changes in Schizophrenia

Modern neuroimaging and research techniques have revealed significant brain changes associated with schizophrenia, though these findings represent group averages rather than individual diagnostic markers.

Structural Brain Changes

Structural, functional, and neurochemical brain alterations implicate multiple regions and functional circuits. Key findings include:

Volume reductions: Decreased gray matter volume in frontal and temporal regions
Ventricular enlargement: Increased size of brain ventricles (fluid-filled spaces)
White matter alterations: Disrupted connections between brain regions
Progressive changes: Some brain changes may progress over time, particularly in early stages

Neurotransmitter Systems

Dopamine dysfunction: Overactivity in some brain regions (linked to positive symptoms) and underactivity in others (linked to negative symptoms and cognitive deficits)
Glutamate abnormalities: Reduced NMDA receptor function affecting learning and memory
GABA imbalances: Disrupted inhibitory signaling affecting neural synchrony
Serotonin alterations: Changes affecting mood and perception

Functional Connectivity

Recent research funded by NIMH found a link between low levels of social motivation in people with psychotic disorders and activity in specific brain regions, identifying potential neural markers. Studies show:

Disrupted communication between brain networks
Altered default mode network activity
Impaired coordination between regions during cognitive tasks
Abnormal patterns of brain activation during social processing

Inflammatory Processes

Emerging research suggests immune system involvement:

Increased inflammatory markers in blood and cerebrospinal fluid
Microglial activation in the brain
Potential autoimmune components in some cases
Links between infection, inflammation, and symptom severity

Treatment Options

Treatment for schizophrenia has advanced significantly, with multiple evidence-based options available. The earlier treatment begins, the better the chances for recovery and improved quality of life. Medication and therapy can help manage symptoms, and in many cases, people with schizophrenia can pursue their goals, have healthy relationships, keep jobs, and be productive members of their communities.

Antipsychotic Medications

First-line treatment typically involves antipsychotic medications, which work primarily by modulating dopamine activity:

Second-Generation Antipsychotics (Atypical)

Generally preferred due to lower risk of movement side effects
Examples include risperidone, olanzapine, quetiapine, aripiprazole, and others
From 2008 to December 31, 2024, the FDA approved 29 medications for schizophrenia including 13 long-acting injectables

Long-Acting Injectable (LAI) Formulations

Administered monthly or every few months
Improve medication adherence
Reduce relapse risk
Particularly helpful for individuals with adherence challenges

Novel Medications

Recent developments include KarXT, a muscarinic receptor agonist, which significantly reduced acute psychotic symptoms in phase 3 trials, representing a new mechanism of action beyond dopamine blockade.

Psychosocial Interventions

Evidence-based psychosocial treatments are essential components of comprehensive care:

Cognitive Behavioral Therapy (CBT)

Meta-analysis of 15 studies involving 1,311 participants showed CBT significantly improved negative symptoms in patients with schizophrenia. CBT helps with:

Managing distressing symptoms
Improving coping strategies
Reducing the impact of hallucinations and delusions
Enhancing medication adherence

Family Therapy

Educates families about schizophrenia
Improves communication patterns
Reduces family stress and criticism
Enhances treatment engagement

Social Skills Training

Improves interpersonal communication
Teaches daily living skills
Enhances community functioning
Builds confidence in social situations

Cognitive Remediation

Cognitive remediation, metacognitive training, and social skills training can be fully considered evidence-based treatments, helping to:

Improve attention and memory
Enhance problem-solving abilities
Strengthen executive functioning
Support vocational goals

Supported Employment

Individual placement and support (IPS) model
Rapid job search assistance
Ongoing workplace support
Integration with mental health treatment

Emerging and Complementary Approaches

Digital Therapeutics

CT-155, a digital therapeutic that received FDA breakthrough device designation in January 2024, was designed with input from patient groups and shows promise for addressing negative symptoms.

Exercise and Lifestyle Interventions

Regular physical activity improves both physical and mental health
Dietary modifications support overall wellness
Sleep hygiene enhances symptom management
Stress reduction techniques promote stability

Peer Support Services

Lived experience provides unique understanding
Reduces isolation and stigma
Promotes hope and recovery
Complements professional treatment

Treatment-Resistant Schizophrenia

For individuals who don't respond adequately to standard treatments:

Clozapine: The most effective antipsychotic for treatment-resistant cases, though requires regular blood monitoring
Augmentation strategies: Adding medications or combining treatments
Electroconvulsive therapy (ECT): For people who do not respond to medication, ECT may be an option. This brain stimulation technique passes small electric currents through the brain to ease symptoms
Comprehensive reassessment: Reviewing diagnosis, adherence, substance use, and psychosocial factors

Early Intervention Programs

Early intervention has revolutionized schizophrenia treatment outcomes. Research strongly supports the first few years after psychotic symptoms start as a critical period for intervention. If left untreated, schizophrenia often becomes more complicated. The World Health Organization recommends no more than 90 days between symptom onset and specialized treatment.

Coordinated Specialty Care (CSC)

CSC represents the gold standard for early psychosis intervention:

Team-based approach: Psychiatrists, therapists, case managers, employment specialists, and peer supporters
Shared decision-making: Individuals and families actively participate in treatment planning
Comprehensive services: Medication management, therapy, family education, and vocational support
Recovery-focused: Emphasizes returning to school, work, and meaningful activities

RAISE Initiative Impact

In 2020, SAMHSA reported that 340 CSC programs operated in all 50 states—a 30-fold increase compared to pre-RAISE years. Over 22,000 youth received care in 2020, compared to several hundred a decade earlier.

Clinical High-Risk Programs

Programs provide trauma-informed, evidence-based interventions to youth and young adults up to 25 years who are at clinical high risk for psychosis, offering:

Early identification of at-risk individuals
Preventive interventions
Monitoring and support
Family engagement
Connection to resources

Duration of Untreated Psychosis (DUP)

Reducing DUP is crucial for better outcomes:

Shorter DUP associated with better treatment response
Improved functional outcomes
Reduced symptom severity
Better long-term prognosis

Access and Implementation

Efforts to expand early intervention access include:

Integration with primary care
School-based screening programs
Community education initiatives
Telehealth options for rural areas
Insurance coverage expansion

Living with Schizophrenia

Recovery and Prognosis

Recent meta-analyses debunk the myth that schizophrenia inevitably has a deteriorating course. Recovery is certainly possible. However, schizophrenia remains a severe and complex mental disorder. Long-term studies show:

Approximately 20-25% achieve full recovery
40-50% experience significant improvement
Many individuals lead fulfilling lives with ongoing support
Early intervention dramatically improves outcomes

Managing Relationships

Schizophrenia can impact relationships, but many individuals maintain meaningful connections:

Open communication: Sharing experiences and needs with trusted individuals
Setting boundaries: Balancing social interaction with self-care needs
Couples therapy: Addressing relationship challenges specific to mental health
Intimacy concerns: Working through medication effects and symptom-related challenges
Family involvement: Engaging loved ones in treatment when helpful

Education and Employment

With proper support, many individuals with schizophrenia pursue educational and career goals:

Academic accommodations: Extended time, reduced course loads, quiet testing environments
Vocational rehabilitation: Skills training and job placement assistance
Supported employment: Ongoing workplace support and job coaching
Disclosure decisions: Weighing benefits and risks of sharing diagnosis
Career flexibility: Finding work that accommodates symptom fluctuations

Physical Health Management

People with schizophrenia face increased physical health risks requiring proactive management:

Meta-analysis of 32 observational studies with over 2 million individuals with schizophrenia found significantly increased risk of type 2 diabetes, with an economic burden of $343.2 billion in 2019. Key health considerations include:

Metabolic monitoring: Regular checks for weight, blood sugar, and lipids
Cardiovascular health: Blood pressure management and heart health screening
Lifestyle factors: Addressing smoking, diet, and physical activity
Medication side effects: Balancing benefits with metabolic risks
Integrated care: Coordinating mental and physical health treatment

Stigma and Advocacy

Reducing stigma remains crucial for improving outcomes:

Self-advocacy: Learning to speak up for needs and rights
Peer support: Connecting with others who understand the experience
Education: Helping others understand schizophrenia accurately
Media representation: Advocating for respectful, accurate portrayals
Policy engagement: Supporting mental health parity and access initiatives

Daily Living Strategies

Practical strategies for managing daily life:

Routine establishment: Creating structure to support stability
Symptom tracking: Monitoring warning signs and triggers
Medication management: Using pill organizers, apps, or pharmacy services
Stress reduction: Implementing relaxation techniques and coping strategies
Social connection: Maintaining relationships while respecting personal limits

Frequently Asked Questions

What causes schizophrenia?

Schizophrenia results from complex interactions between genetic vulnerability and environmental factors. No single cause exists, but risk factors include family history, prenatal complications, childhood trauma, and substance use. Brain chemistry imbalances, particularly involving dopamine and glutamate, play important roles.

Can schizophrenia be cured?

While there's no cure for schizophrenia, many people achieve remission of symptoms and lead fulfilling lives. Early intervention, consistent treatment, and comprehensive support significantly improve outcomes. Recovery is an ongoing process focused on managing symptoms and maximizing quality of life.

How is schizophrenia different from multiple personality disorder?

Schizophrenia and dissociative identity disorder (formerly multiple personality disorder) are entirely different conditions. Schizophrenia involves disruptions in thinking, perception, and emotions, while dissociative identity disorder involves distinct identity states. The "split" in schizophrenia refers to fragmented mental functions, not multiple personalities.

What should family members know about supporting someone with schizophrenia?

Family support significantly impacts recovery. Key approaches include learning about the condition, maintaining realistic expectations, encouraging treatment adherence, reducing criticism and emotional intensity, participating in family therapy, and taking care of your own mental health. Remember that recovery is possible with proper support.

Are people with schizophrenia dangerous?

Most people with schizophrenia are not violent and are more likely to be victims than perpetrators of violence. When violence does occur, it's usually related to untreated symptoms, substance use, or specific delusions. Proper treatment dramatically reduces any risk and helps individuals live peacefully in their communities.

How can I find appropriate treatment?

Start by consulting with a primary care provider who can provide referrals to mental health specialists. Look for programs specializing in psychosis or schizophrenia, particularly early intervention programs if symptoms recently began. Consider comprehensive treatment centers offering both medication management and psychosocial services. Many areas have specialized first-episode psychosis programs providing coordinated specialty care.

How Therapy Can Help

Professional mental health treatment is essential for managing schizophrenia effectively. Working with qualified therapists and psychiatrists provides numerous benefits beyond medication management.

Individual therapy helps people with schizophrenia develop coping strategies, process difficult experiences, and work toward personal goals. Therapists trained in evidence-based approaches like CBT for psychosis can help individuals:

Challenge distressing thoughts and beliefs
Develop reality-testing skills
Improve social functioning
Build self-esteem and confidence
Address trauma and co-occurring conditions

Group therapy offers unique benefits through peer interaction and support. Participants can practice social skills, share experiences, and learn from others facing similar challenges. Groups focused on specific skills like emotion regulation or vocational preparation provide targeted support.

Family therapy strengthens the entire support system. When families understand schizophrenia and learn effective communication strategies, outcomes improve significantly. Family work reduces stress, prevents relapse, and creates a more supportive home environment.

Integrated treatment addressing both mental health and substance use is crucial, as many individuals with schizophrenia also struggle with addiction. Dual diagnosis programs provide comprehensive care for co-occurring conditions.

If you or a loved one is experiencing symptoms of schizophrenia, reaching out for professional help is a crucial first step. The [GoodTherapy directory](https://www.goodtherapy.org/find-therapist.html) can connect you with qualified mental health professionals in your area who specialize in treating psychotic disorders. Many therapists offer evidence-based treatments specifically designed for schizophrenia and can work collaboratively with psychiatrists to ensure comprehensive care.

Remember, seeking help is a sign of strength, not weakness. With proper treatment and support, people with schizophrenia can achieve their goals, maintain relationships, and lead meaningful lives. The journey to recovery begins with reaching out for professional support.

References:

If you or a loved one is experiencing symptoms of schizophrenia, reaching out for professional help is a crucial first step. The [GoodTherapy directory](https://www.goodtherapy.org/find-therapist.html) can connect you with qualified mental health professionals in your area who specialize in treating psychotic disorders. Many therapists offer evidence-based treatments specifically designed for schizophrenia and can work collaboratively with psychiatrists to ensure comprehensive care.
Abdelmoteleb, S., Totlani, J., Ramadan, S., Salem, M., Meyer, A., Chang, T., Ewing, M., Freire, L., Murphy, N., Renteria, S., Dymkoski, R., Liran, O., Hedrick, R., Danovitch, I., Pechnick, R. N., & IsHak, W. W. (2025). Schizophrenia management: Systematic review of current medications and Phase-3 agents (2008-2024). Neuroscience Applied, 4, 105507. https://doi.org/10.1016/j.nsa.2025.105507
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
Azrin, S., Goldstein, A., Heinssen, R., Bowers, A., Cottingham, M., Bennett, M. E., & Dixon, L. (2023). RAISE-ing the standard of care for schizophrenia: The rapid adoption of coordinated specialty care in the United States. National Institute of Mental Health. https://www.nimh.nih.gov/news/science-updates/2023/raise-ing-the-standard-of-care-for-schizophrenia
Berendsen, S., Berendse, S., van der Torren, J., Schoevers, R., Wijnen, B., Lokkerbol, J., de Winter, R., Klein Brinke, N., & Pijnenborg, G. (2024). Cognitive behavioural therapy for the treatment of schizophrenia spectrum disorders: An umbrella review of meta-analyses of randomised controlled trials. eClinicalMedicine, 67, 102392. https://doi.org/10.1016/j.eclinm.2023.102392
Bighelli, I., Rodolico, A., García-Mieres, H., Pitschel-Walz, G., Hansen, W. P., Schneider-Thoma, J., Siafis, S., Wu, H., Wang, D., Salanti, G., Furukawa, T. A., Barbui, C., & Leucht, S. (2024). Evidence-based psychosocial interventions in schizophrenia: A critical review. Current Opinion in Psychiatry, 37(3), 131-139. https://doi.org/10.1097/YCO.0000000000000920
California Mental Health Services Oversight and Accountability Commission. (2024). Strategic plan for early psychosis care. https://bhsoac.ca.gov/wp-content/uploads/10_01_DRAFT_EPI_StrategicPlan_07252024.pdf
Correll, C. U., Abi-Dargham, A., Howes, O., & Kane, J. M. (2023). New developments in the treatment of schizophrenia: An expert roundtable. International Journal of Neuropsychopharmacology, 26(5), 322-330. https://doi.org/10.1093/ijnp/pyad018
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., & Tiihonen, J. (2022). Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry, 21(2), 248-271. https://doi.org/10.1002/wps.20994
Dong, P., Wen, X., Liu, J., Zhang, S., Li, J., Jiang, J., Zhou, C., Xie, C., Zhao, K., Liu, L., Shen, Z., Zhang, D., Sun, L., Zhang, S., Jin, C., & Li, M. (2023). Convergence of the dysregulated regulome in schizophrenia with polygenic risk and evolutionarily constrained enhancers. Molecular Psychiatry, 28(4), 1-11. https://doi.org/10.1038/s41380-023-02027-w
Duerr, H. A. (2025). 2025 Schizophrenia insights: Ending the year with positive data. Psychiatric Times. https://www.psychiatrictimes.com/view/2025-schizophrenia-insights-ending-the-year-with-positive-data
FAIR Health. (2024). Trends in mental health conditions: An analysis of private healthcare claims 2019-2023. https://s3.amazonaws.com/media2.fairhealth.org/whitepaper/asset/Trends%20in%20Mental%20Health%20Conditions%20-%20A%20FAIR%20Health%20White%20Paper.pdf
Girdhar, K., Hoffman, G. E., Bendl, J., Rahman, S., Dong, P., Liao, W., Hauberg, M. E., Sloofman, L., Brown, L., Devillers, O., Kassim, B. S., Wiseman, J. R., Park, R., Zharovsky, E., Jacobov, E., Flatow, E., Kozlenkov, A., Gilgenast, T., Johnson, J. S.,... Roussos, P. (2022). Chromatin domain alterations linked to 3D genome organization in a large cohort of schizophrenia and bipolar disorder brains. Nature Neuroscience, 25(4), 474-483. https://doi.org/10.1038/s41593-022-01032-6
Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2023). A systematic review and meta-analysis of the association between psychopathology and social functioning in schizophrenia. Schizophrenia Bulletin, 49(6), 1470-1485. https://doi.org/10.1093/schbul/sbad075
Hong, Y., & Chen, Y. (2025). Cognitive-behavioral therapy for the improvement of negative symptoms and functioning in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 20(5), e0324685. https://doi.org/10.1371/journal.pone.0324685
Interdepartmental Serious Mental Illness Coordinating Committee. (2024). Report to Congress: Advances in serious mental illness research and treatment. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/sites/default/files/ismicc-rtc-2024.pdf
Iruretagoyena, B., Rubio, J. M., Aranguren, N., González-Torres, M. Á., & Undurraga, J. (2025). Core beliefs in psychosis: A systematic review and meta-analysis. Schizophrenia, 11, Article 38. https://doi.org/10.1038/s41537-025-00577-2
Jimenez, A. M., Clayson, P. E., Hasratian, A. S., Lee, J., Reavis, E. A., Wynn, J. K., Green, M. F., & Horan, W. P. (2023). Neuroimaging of social motivation during winning and losing: Associations with social anhedonia across the psychosis spectrum. Neuropsychologia, 188, Article 108621. https://doi.org/10.1016/j.neuropsychologia.2023.108621
Kaul, I., Sawchak, S., Walling, D. P., Breier, A., Zhu, H., Miller, A. C., Paul, S. M., & Brannan, S. K. (2024). Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiatry, 81(2), 149-156. https://doi.org/10.1001/jamapsychiatry.2023.4176
Leucht, S., Schneider-Thoma, J., Burschinski, A., Peter, N., Wang, D., Dong, S., Samara, M. T., Nikolakopoulou, A., Salanti, G., & Davis, J. M. (2023). Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: Systematic review and network meta-analysis. World Psychiatry, 22(2), 315-324. https://doi.org/10.1002/wps.21089
Malda, A., Boonstra, N., Barf, H., de Jong, S., Aleman, A., Addington, J., Pruessner, M., Nieman, D., de Haan, L., Morrison, A., Riecher-Rössler, A., Studerus, E., Ruhrmann, S., Schultze-Lutter, F., An, S. K., Koike, S., Kasai, K., Nelson, B., McGorry, P.,... Pijnenborg, G. H. M. (2023). The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. Schizophrenia Research, 250, 152-163. https://doi.org/10.1016/j.schres.2022.11.010
McCutcheon, R. A., Marques, T. R., & Howes, O. D. (2020). Schizophrenia—An overview. JAMA Psychiatry, 77(2), 201-210. https://doi.org/10.1001/jamapsychiatry.2019.3360
McCutcheon, R. A., Taylor, D., Rubio, J., Nour, M. M., Pillinger, T., Murray, R. M., McCleery, A., Demjaha, A., Flanagan, R., & Howes, O. D. (2025). International guidelines for algorithmic treatment of schizophrenia (INTEGRATE). The Lancet Psychiatry. Published online March 31, 2025. https://doi.org/10.1016/S2215-0366(25)00031-8
National Institute of Mental Health. (2024). Schizophrenia. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/topics/schizophrenia
Parnas, J., Nordgaard, J., & Henriksen, M. G. (2023). Disordered selfhood in schizophrenia: A clinical research perspective. Harvard Review of Psychiatry, 31(5), 233-247. https://doi.org/10.1097/HRP.0000000000000381
Singh, T., Neale, B. M., Daly, M. J., & Schizophrenia Exome Meta-Analysis (SCHEMA) Consortium. (2023). Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature, 618(7966), 819-827. https://doi.org/10.1038/s41586-023-06208-z
Solmi, M., Seitidis, G., Mavridis, D., Correll, C. U., Dragioti, E., Guimond, S., Tuominen, L., Dargél, A., Carvalho, A. F., Fornaro, M., Maes, M., Monaco, F., Song, M., Il Shin, J., Cortese, S., & Radua, J. (2023). Incidence, prevalence, and global burden of schizophrenia - Data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry, 28(12), 5319-5327. https://doi.org/10.1038/s41380-023-02138-4
Substance Abuse and Mental Health Services Administration. (2024). Community programs for outreach and intervention with youth and young adults at clinical high risk for psychosis (Grant Announcement SM-24-007). https://www.samhsa.gov/grants/grant-announcements/sm-24-007
Substance Abuse and Mental Health Services Administration. (2025). What is schizophrenia? U.S. Department of Health and Human Services. https://www.samhsa.gov/mental-health/what-is-mental-health/conditions/schizophrenia
Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., Schultz, S., Tsuang, M., Van Os, J., & Carpenter, W. (2024). The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophrenia Research, 264, 1-17. https://doi.org/10.1016/j.schres.2023.12.001
Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T. B., Bryois, J., Chen, C. Y., Dennison, C. A., Hall, L. S., Lam, M., Watanabe, K., Frei, O., Ge, T., Harwood, J. C., Koopmans, F., Magnusson, S., Richards, A. L., Sidorenko, J.,... Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2022). Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 604(7906), 502-508. https://doi.org/10.1038/s41586-022-04434-5
van Dee, V., Schnack, H. G., & Cahn, W. (2023). Systematic review and meta-analysis on predictors of prognosis in patients with schizophrenia spectrum disorders: An overview of current evidence and a call for prospective research and open access to datasets. Schizophrenia Research, 254, 133-142. https://doi.org/10.1016/j.schres.2023.02.024
Zeng, B., Ardekani, B. A., Tang, Y., Zhang, T., Zhao, S., Cui, H., Fan, X., Zhuo, K., Li, C., Xu, Y., Goff, D. C., & Wang, J. (2024). Genetic regulation of cell type-specific chromatin accessibility shapes brain disease etiology. Science, 384(6698), eadh4265. https://doi.org/10.1126/science.adh4265
Zhou, Y., Song, X., Guo, Y., Lang, X., Li, Z., & Zhang, X. H. (2024). Schizophrenia and type 2 diabetes risk: A systematic review and meta-analysis. Frontiers in Endocrinology, 15, 1395771. https://doi.org/10.3389/fendo.2024.1395771